Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25299562 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ABL1CYP2D6CSNK1DPIK3CG | |
| SCHEMBL25833539 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ABL1CYP2D6CSNK1DPIK3CG | |
| SCHEMBL30450160 | 0.92 | ALDH1A1 (0.62) | ALDH1A1ABL1CYP2D6CSNK1DPIK3CG | |
| SCHEMBL25262799 | 0.92 | ALDH1A1 (0.62) | ALDH1A1ABL1CYP2D6CSNK1DPIK3CG | |
| SCHEMBL25833569 | 0.92 | ALDH1A1 (0.62) | ALDH1A1ABL1CYP2D6CSNK1DPIK3CG | |
| SCHEMBL30451396 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CYP2D6CSNK1DDYRK1A | |
| SCHEMBL25833329 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CYP2D6CSNK1DDYRK1A | |
| SCHEMBL25300056 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CYP2D6CSNK1DDYRK1A | |
| SCHEMBL25302804 | 0.84 | ALDH1A1 (0.58) | ALDH1A1ABL1PIK3CGKITPDGFRA | |
| SCHEMBL30450602 | 0.84 | ALDH1A1 (0.64) | ALDH1A1ABL1CYP2D6PIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | claimed |
| CN-118660885-A | Norbornene analogs and their use as potentiators of antitubercular drugs | 国家医疗保健研究所 | 2024-09-17 | — | — | CN | claimed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | claimed |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118660885-A | Norbornene analogs and their use as potentiators of antitubercular drugs | 国家医疗保健研究所 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | ALDH1A1 108/4885ABL1 1172/4885CYP2D6 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.